{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:48:07Z","timestamp":1784882887549,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:00:00Z","timestamp":1378425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Laboratory (<jats:styled-content style=\"fixed-case\">LTLS<\/jats:styled-content>) and clinical (<jats:styled-content style=\"fixed-case\">CTLS<\/jats:styled-content>) tumour lysis syndrome (<jats:styled-content style=\"fixed-case\">TLS<\/jats:styled-content>) are frequent complications in newly diagnosed children with advanced mature B cell non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>). Rasburicase, compared to allopurinol, results in more rapid reduction of uric acid in paediatric patients at risk for <jats:styled-content style=\"fixed-case\">TLS<\/jats:styled-content>. However, the safety and efficacy of rasburicase for the treatment or or prevention of <jats:styled-content style=\"fixed-case\">TLS<\/jats:styled-content> has not been prospectively evaluated. Children with newly diagnosed stage <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>, bone marrow<jats:sup>+<\/jats:sup> and\/or central nervous system<jats:sup>+<\/jats:sup> mature <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> received hydration and rasburicase prior to cytoreductive therapy. Rasburicase was safe and well\u2010tolerated and there were no grade III\u2013IV toxicities probably or directly related to rasburicase. Patients with an initial lactate dehydrogenase \u22652\u00d7 upper limit of normal had a significantly elevated uric acid level (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b7005), increased incidence of <jats:styled-content style=\"fixed-case\">TLS<\/jats:styled-content> (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u22120\u00b7005) and lower glomerular filtration rate (<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>;<jats:italic> <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0&lt;\u00a00\u00b7001). Following rasburicase, there was only a 9% and 5% incidence of <jats:styled-content style=\"fixed-case\">LTLS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">CTLS<\/jats:styled-content>, respectively. Furthermore, there was a significant improvement in estimated <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content> from <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ay 0 to <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ay 7 following rasburicase (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0=\u00a00\u00b70007) and only 1\u00b73% of patients required new onset renal assisted support after rasburicase administration. A <jats:styled-content style=\"fixed-case\">TLS<\/jats:styled-content> strategy incorporating rasburicase prior to cytoreductive chemotherapy proved safe and effective in preventing new onset renal failure and was associated with a significant improvement in <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12542","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T07:29:17Z","timestamp":1378452557000},"page":"365-372","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature <scp>B<\/scp>\u2010<scp>NHL<\/scp>: a <scp>C<\/scp>hildren's <scp>O<\/scp>ncology <scp>G<\/scp>roup <scp>R<\/scp>eport"],"prefix":"10.1111","volume":"163","author":[{"given":"Paul J.","family":"Galardy","sequence":"first","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hochberg","sequence":"additional","affiliation":[{"name":"New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Perkins","sequence":"additional","affiliation":[{"name":"University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[{"name":"New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanton","family":"Goldman","sequence":"additional","affiliation":[{"name":"Medical City Children's Hospital Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1200\/jco.2010.28.15_suppl.9536","article-title":"Safety, kinetics and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III\/IV (Group B) and BM+\/CNS+ (Group C) mature B\u2010NHL: a Children's Oncology Group Report","volume":"28","author":"Cairo M.S.","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90174-N"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12327"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90037-X"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09024.x"},{"key":"e_1_2_8_14_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400850"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.697"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)36251-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043892"},{"key":"e_1_2_8_20_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"Wossmann W.","year":"2003","journal-title":"Annals of Hematology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12542","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:06:40Z","timestamp":1696363600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/bjh.12542"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12542","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,6]]},"assertion":[{"value":"2013-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}